SCHEMBL4374701

SCHEMBL4374701

Cc1c(C)c2c(c(C)c1OP(=O)(O)O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2.[NaH]

nearest known ligand 0.98

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 2/20 0.98
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
PDE4A P27815 1/20 0.72
PDE3A Q14432 1/20 0.72
PSEN1 P49768 2/20 0.69
LMNA P02545 3/20 0.67
TTPA P49638 3/20 0.67
MAPT P10636 2/20 0.67
GSTP1 P09211 1/20 0.67
USP2 O75604 1/20 0.67
THRB P10828 1/20 0.67
CYP2C9 P11712 1/20 0.67
CYP2C19 P33261 1/20 0.67
PTPN1 P18031 1/20 0.66
NR1I2 O75469 3/20 0.58
ALOX5 P09917 1/20 0.56
PGR P06401 1/20 0.50
AKT1 P31749 3/20 0.48
PDPK1 O15530 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2507605 0.99 GSTO1 (1.00) GSTO1MEN1KMT2APDE4APDE3A
SCHEMBL17080738 0.99 GSTO1 (1.00) GSTO1MEN1KMT2APDE4APDE3A
SCHEMBL10476840 0.99 GSTO1 (1.00) GSTO1MEN1KMT2APDE4APDE3A
SCHEMBL15960056 0.99 GSTO1 (1.00) GSTO1MEN1KMT2APDE4APDE3A
SCHEMBL18785106 0.99 GSTO1 (1.00) GSTO1MEN1KMT2APDE4APDE3A
SCHEMBL278119 0.93 GSTO1 (0.89) GSTO1MEN1KMT2APDE4APDE3A
SCHEMBL29691219 0.93 GSTO1 (0.89) GSTO1MEN1KMT2APDE4APDE3A
SCHEMBL23805544 0.90 GSTO1 (0.84) GSTO1MEN1KMT2APDE4APDE3A
SCHEMBL21257304 0.90 GSTO1 (0.84) GSTO1MEN1KMT2APDE4APDE3A
SCHEMBL21204341 0.89 GSTO1 (0.82) GSTO1MEN1KMT2APDE4APDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140072617-A1 METHOD FOR PREVENTING OR SLOWING DOWN THE APPEARANCE OF THE EFFECTS OF SKIN AGEING USING A TOCOPHERYL PHOSPHATE IN LIPOSOMES LVMH RECHERCHE (FR) 2014-03-13 US disclosed
US-20090104258-A1 Use of tocopheryl phosphate as an agent for preventing or slowing down the appearance of the effects of skin ageing LVMH RECHERCHE (FR) 2009-04-23 US disclosed
US-20080039625-A1 Screening Methods LAUTENS MARK 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039625-A1 Screening Methods CBR3, ZKSCAN2, CRBN GSTO1 413/4885MEN1 1787/4885KMT2A 3795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.